Predictors of timely linkage-to-ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested case-control study

Kalpana Sabapathy, Constance Mubekapi-Musadaidzwa, Chama Mulubwa, Ab Schaap, Graeme Hoddinott, Anne Stangl, Sian Floyd, Helen Ayles, Sarah Fidler, Richard Hayes, HPTN 071 (PopART) study team, Kalpana Sabapathy, Constance Mubekapi-Musadaidzwa, Chama Mulubwa, Ab Schaap, Graeme Hoddinott, Anne Stangl, Sian Floyd, Helen Ayles, Sarah Fidler, Richard Hayes, HPTN 071 (PopART) study team

Abstract

Introduction: HPTN 071 (PopART) is a three-arm community randomized trial in Zambia and South Africa evaluating the impact of a combination HIV prevention package, including universal test and treat (UTT), on HIV incidence. This nested study examined factors associated with timely linkage-to-care and ART initiation (TLA) (i.e. within six-months of referral) in the context of UTT within the intervention communities of the HPTN 071 (PopART) trial.

Methods: Of the 7572 individuals identified as persons living with HIV (PLWH) (and not on antiretroviral treatment (ART)) during the first year of the PopART intervention provided by Community HIV-care Providers (CHiPs) through door-to-door household visits, individuals who achieved TLA (controls) and those who did not (cases), stratified by gender and community, were randomly selected to be re-contacted for interview. Standardized questionnaires were administered to explore factors potentially associated with TLA, including demographic and behavioural characteristics, and participants' opinions on HIV and related services. Odds ratios comparing cases and controls were estimated using a multi-variable logistic regression.

Results: Data from 705 participants (333 cases/372 controls) were analysed. There were negligible differences between cases and controls by demographic characteristics including age, marital or socio-economic position. Prior familiarity with the CHiPs encouraged TLA (aOR of being a case: 0.58, 95% CI: 0.39 to 0.86, p = 0.006). Participants who found clinics overcrowded (aOR: 1.51, 95% CI: 1.08 to 2.12, p = 0.006) or opening hours inconvenient (aOR: 1.63, 95% CI: 1.06 to 2.51, p = 0.02) were less likely to achieve TLA, as were those expressing stronger feelings of shame about having HIV (ptrend = 0.007). Expressing "not feeling ready" (aOR: 2.75, 95% CI: 1.89 to 4.01, p < 0.001) and preferring to wait until they felt sick (aOR: 2.00, 95% CI: 1.27 to 3.14, p = 0.02) were similarly indicative of being a case. Worrying about being seen in the clinic or about how staff treated patients was not associated with TLA. While the association was not strong, we found that the greater the number of self-reported lifetime sexual partners the more likely participants were to achieve TLA (ptrend = 0.06). There was some evidence that participants with HIV-positive partners on ART were less likely to be cases (aOR: 0.75, 95% CI: 0.53 to 1.06, p = 0.07).

Discussion: The lack of socio-demographic differences between cases and controls is encouraging for a "universal" intervention that seeks to ensure high coverage across whole communities. Making clinics more "patient-friendly" could enhance treatment uptake further. The finding that those with higher risk behaviour are more actively engaging with UTT holds promise for treatment-as-prevention.

Keywords: ART initiation; cascade of care; differentiated care; immediate ART; linkage to care; treatment as prevention; universal test and treat; universal treatment.

© 2017 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society.

Figures

Figure 1
Figure 1
Overview of the HPTN 071 (PopART) trial.
Figure 2
Figure 2
Case and control selection process.

References

    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV‐1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
    1. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.
    1. INSIGHT START Study Group . Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
    1. TEMPRANO ANRS Study Group . A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.
    1. World Health Organization . Guideline on when to start antiretroviral therapy and on pre‐exposure prophylaxis for HIV. 2015. [cited 2016 Feb 26] Available from:
    1. Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster‐randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment ‐ a study protocol for a cluster randomised trial. Trials. 2014;15:57.
    1. Hayes R, Floyd S, Schaap A, Shanaube K, Bock P, Sabapathy K, et al. A universal testing and treatment intervention to improve HIV control: one‐year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster‐randomised trial. PLoS Med. 2017;14(5):e1002292.
    1. Aliyu MH, Blevins M, Parrish DD, Megazzini KM, Gebi UI, Muhammad MY, et al. Risk factors for delayed initiation of combination antiretroviral therapy in rural north central Nigeria. J Acquir Immune Defic Syndr. 2014;65(2):e41–9.
    1. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss‐to‐follow‐up during the pre‐treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
    1. Feldacker C, Johnson D, Hosseinipour M, Phiri S, Tweya H. Who starts? Factors associated with starting antiretroviral therapy among eligible patients in two, public HIV clinics in Lilongwe, Malawi. PLoS One. 2012;7(11):e50871.
    1. Fox MP, Shearer K, Maskew M, Meyer‐Rath G, Clouse K, Sanne I. Attrition through multiple stages of pre‐treatment and ART HIV care in South Africa. PLoS One. 2014;9(10):e110252.
    1. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV‐infected adults. AIDS. 2011;25(17):2177–81.
    1. McGrath N, Glynn JR, Saul J, Kranzer K, Jahn A, Mwaungulu F, et al. What happens to ART‐eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi. BMC Public Health. 2010;10:601.
    1. Boyer S, Iwuji C, Gosset A, Protopopescu C, Okesola N, Plazy M, et al. Factors associated with antiretroviral treatment initiation amongst HIV‐positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care. 2016;28 Suppl 3:39–51.
    1. Iwuji C, Orne‐Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, et al. The impact of universal test and treat on HIV incidence in a rural South African population: ANRS 12249 TasP trial, 2012‐2016. 2016. [cited 2016 Oct 19]. Available from:
    1. Babor TF, Higgins‐Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorders Identification Test ‐ guidelines for use in primary care. 2001. [cited 2017 Feb 6]. Available from:
    1. MacPherson P, MacPherson EE, Mwale D, Bertel Squire S, Makombe SD, Corbett EL, et al. Barriers and facilitators to linkage to ART in primary care: a qualitative study of patients and providers in Blantyre, Malawi. J Int AIDS Soc. 2012;15(2):18020.
    1. UNAIDS . 90‐90‐90: an ambitious treatment target to help end the AIDS epidemic. 2014. [cited 2016 Jan 11] Available from:
    1. Petersen M, Balzer L, Kwarsiima D, Sang N, Chamie G, Ayieko J, et al. Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa. JAMA. 2017;317(21):2196–206.
    1. Rachlis B, Bakoyannis G, Easterbrook P, Genberg B, Braithwaite RS, Cohen CR, et al. Facility‐level factors influencing retention of patients in HIV care in East Africa. PLoS One. 2016;11(8):e0159994.
    1. Siedner MJ, Ng CK, Bassett IV, Katz IT, Bangsberg DR, Tsai AC. Trends in CD4 count at presentation to care and treatment initiation in sub‐Saharan Africa, 2002‐2013: a meta‐analysis. Clin Infect Dis. 2015;60(7):1120–7.
    1. Goffman E. Stigma: notes on the management of spoiled identity. London: Penguin; 1963.
    1. Rao D, Desmond M, Andrasik M, Rasberry T, Lambert N, Cohn SE, et al. Feasibility, acceptability, and preliminary efficacy of the unity workshop: an internalized stigma reduction intervention for African American women living with HIV. AIDS Patient Care STDS. 2012;26(10):614–20.
    1. Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to reduce HIV‐related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS Soc. 2013;16 3 Suppl 2:18734.
    1. Koenig SP, Dorvil N, Devieux JG, Hedt‐Gauthier BL, Riviere C, Faustin M, et al. Same‐day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLoS Med. 2017;14(7):e1002357.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner